ArticleFrontiers in molecular neuroscience2026
Integrating neural organoids and AI: increasing the risk of artificial consciousness or medical malpractice?
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neural organoids can be integrated with AI models in various formats, termed AI-NO systems. Neural organoids and AI are each high impact research fields which may play significant roles in biological research and clinical decision making. However, their potential benefits, pitfalls and associated governance structures are often overshadowed by highly speculative discourse over the possibility of them developing some form of consciousness and subsequently acquiring a level of moral status. This article examines the cause for this speculative discourse, arguing for a focus on more immediate, empirically grounded ethical issues. It describes potential ethical issues when data obtained from AI models is used for research planning and drug discovery on neural organoids; when AI models are used to analyze data obtained from neural organoids; and when AI models are used to control interventions on neural organoids in open- or closed-loop configurations. It concludes with an investigation on how AI-NO systems may impact clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.